| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | Azenosertib (ZN-c3) advanced solid tumors, ovarian cancer | NDA | — | Nanomedicine | Oncology | ||
NDA Filing example | Azenosertib (ZN-c3) advanced solid tumors, ovarian cancer | NDA | — | Nanomedicine | Oncology | ||
NDA Filing example | Azenosertib (ZN-c3) advanced solid tumors, ovarian cancer | NDA | — | Nanomedicine | Oncology |
Recent Updates
Recently added Catalysts
Zentalis Pharmaceuticals, Inc.$3.81
+0.02 (+0.66%)
C 45Pipeline Score Overvalued Biotech · Clinical
Market Cap
289.02 M
EPS
-1.74
P/E Ratio
-
Value Trade
4.35 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
28.72 M
Operating CF
-32.96 M
Total Assets
253.07 M
Total Liabilities
70.39 M
Equity
182.68 M
D/E Ratio
12,345
1.5 %
Week
0.25 %
1 Month
61.75 %
3 Month
212.31 %
6 Month
-93.21 %
5 Year
-83.89 %
All Time
Cash Data
Cash Position
211.76 M
Monthly Burn
10.98 M
Runway
17.8 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
721.49 K
52 Week Range
1.13 - 6.95
% held by Insiders
36.08 %
% held by Institutions
52.63 %
Enterprise Value
115.91 M
Total Shares
72.24 M
Short %
10.95 %
Float Shares
46.67 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C45
Pipeline Score $79M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 67%
Micro Cap (rank 300 of 905)
Percentile RankZentalis Pharmaceuticals, Inc. carries a moderate pipeline score (45/100), with $610M risk-adjusted pipeline value, led by Azenosertib in Uterine Serous Carcinoma (Phase 2), across $63B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azenosertib Small molecule | Uterine Serous Carcinoma | Phase 2 | NCT04814108 | 19% | $516M | COMPLETED | 117 | - | - | Oct 22, 2025 | - | MEDIUM May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZNTL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZNTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZNTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZNTL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZNTL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ZNTL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Zentalis Pharmaceuticals announced the grant of non-qualified stock options for 191,000 shares to two new employees under its 2022 Employment Inducement Incentive Award Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent. The stock options will vest over four years, contingent on continued employment.
Read more →ZNTLZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
Zentalis Pharmaceuticals has appointed Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy. These appointments aim to bolster the company's commercial capabilities as it advances its investigational WEE1 inhibitor, azenosertib, through late-stage trials for Cyclin E1-positive platinum-resistant ovarian cancer. The company anticipates significant milestones in its registrational program.
Read more →ZNTLZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals announced promising data from the Phase 1b MUIR trial for azenosertib combined with paclitaxel in treating platinum-resistant ovarian cancer. The trial showed a 39% overall response rate and a median progression-free survival of 7.3 months. The combination demonstrated a manageable safety profile with low rates of high-grade adverse events, indicating potential for broader application in ovarian cancer treatment.
Read more →ZNTLZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Zentalis Pharmaceuticals reported its financial results for Q1 2026, highlighting significant clinical progress with its investigational WEE1 inhibitor, azenosertib. The company selected a pivotal dose for its registration-intended trials and expects topline results from the DENALI Phase 2 trial by the end of 2026. Additionally, the ASPENOVA Phase 3 trial has commenced with the first patient dosed, aiming for full approval in Cyclin E1-positive ovarian cancer.
Read more →ZNTLZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial, dosing its first patient with azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial aims to compare azenosertib to standard chemotherapy and supports the company's strategy for accelerated approval. The study is crucial for addressing the significant unmet needs in this patient population.
Read more →ZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Zentalis Pharmaceuticals announced the grant of stock options to a newly hired employee under its 2022 Employment Inducement Incentive Award Plan. The grant, totaling 26,000 shares, adheres to Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $4.09 per share. The options will vest over four years, contingent on the employee's continued service.
Read more →ZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals announced the grant of 26,000 stock options to a new employee under its 2022 Employment Inducement Incentive Award Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent to support its ongoing development of the WEE1 inhibitor azenosertib for ovarian cancer. The options have a 10-year term and will vest over four years.
Read more →ZNTLZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
Zentalis Pharmaceuticals announced promising preclinical data on azenosertib, a WEE1 inhibitor, in triple-negative breast cancer (TNBC) and highlighted the significant unmet needs in Cyclin E1-positive ovarian cancer patients. The data will be presented at the AACR Annual Meeting 2026, showcasing azenosertib's potential to enhance treatment outcomes. The findings support expanding the drug's application beyond ovarian cancer.
Read more →ZNTLzntlcorporateprese Corporate Presentation April 2026 Nasdaq: ZNTL 2 Zentalis Pharmaceuticals, Inc. ("we," "us," "our," "Zentalis" or the "Company") cautions that this presentation (including oral commentary that accompan
Zentalis Pharmaceuticals, Inc. presented details about its future plans for azenosertib, an investigational drug, including the anticipated momentum in its development program throughout 2026. The presentation highlighted the completion of enrollment in the DENALI Part 2a trial and alignment with FDA on the Phase 3 ASPENOVA trial design. Zentalis has a robust financial foundation with $245.9M in cash as of December 31, 2025. However, the company also acknowledged challenges including the potential for serious side effects and the need for additional funding.
Read more →ZNTLZentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals has selected 400mg QD 5:2 as the optimal monotherapy dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer based on interim analysis from DENALI Part 2a. This dose will be utilized in the ongoing DENALI Phase 2 and ASPENOVA Phase 3 trials. The company is also preparing for commercialization and expanding its clinical pipeline.
Read more →ZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals announced the grant of non-qualified stock options to two new employees as part of its 2022 Employment Inducement Incentive Award Plan. This grant, totaling 36,000 shares, aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent. The options have an exercise price of $2.57 per share and will vest over four years.
Read more →ZNTLZentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Zentalis Pharmaceuticals reported its financial results for 2025 and highlighted key milestones for 2026, including the completion of enrollment for the DENALI Part 2a trial. The company anticipates topline results from this trial by year-end, which could support accelerated approval for its WEE1 inhibitor, azenosertib. Additionally, Zentalis plans to initiate a Phase 3 trial, ASPENOVA, to compare azenosertib with standard chemotherapy.
Read more →ZNTLZentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
Zentalis Pharmaceuticals announced two poster presentations at the AACR Annual Meeting 2026, showcasing their investigational WEE1 inhibitor, azenosertib. The presentations will highlight its potential as a combination therapy for Triple-Negative Breast Cancer and its biomarker-driven approach for ovarian cancer. This research aims to address significant unmet needs in cancer treatment.
Read more →ZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced its participation in upcoming investor conferences, showcasing its innovative WEE1 inhibitor, azenosertib, for ovarian cancer treatment. The company aims to enhance treatment experiences for patients with this first-in-class therapy. However, Zentalis faces challenges such as significant financial losses and uncertainties in clinical trial outcomes.
Read more →ZNTLZentalis Pharmaceuticals to Participate in Upcoming February 2026 Investor Conference
Zentalis Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The management team will discuss their investigational WEE1 inhibitor, azenosertib, which is being developed as a treatment for ovarian cancer. The event will be accessible via a live webcast, with recordings available for 30 days.
Read more →ZNTLZentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and finan
Zentalis Pharmaceuticals announced the appointment of James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Bucher, with over 30 years in the life sciences sector, brings considerable expertise in corporate strategy and legal compliance. He replaces Andrea Paul, who will transition to a role at a large law firm. The leadership expresses optimism that Bucher will aid in advancing the clinical development of azenosertib, a treatment for patients with ovarian cancer.
Read more →ZNTLZentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermitten
Zentalis Pharmaceuticals has announced favorable results for its azenosertib monotherapy, revealing that an intermittent dosing schedule nearly doubles efficacy in heavily pretreated patients with platinum-resistant ovarian cancer and uterine serous carcinoma. The recommended Phase 2 dose (RP2D) is now established at 400 mg daily, demonstrating an improved objective response rate of 36.8%. The new dosing strategy maintains safety and tolerability, with no treatment-related discontinuations reported. The company plans to provide further efficacy data and updates on ongoing Phase 2 trials in the latter half of 2023.
Read more →ZNTLsmith_asco2023xznx A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor Azenosertib (ZN-c3) in Patients (Pts) With Acute Myeloid Leukemia (AML) Catherine Smith1, Pankit Vachhani2, Guiller
A Phase 1/2 dose escalation study is underway assessing the efficacy and safety of the BCL-2 inhibitor ZN-d5 combined with the WEE1 inhibitor azenosertib in patients with relapsed or refractory acute myeloid leukemia (AML). This study aims to establish the maximum tolerated dose and the clinical activity of this combination. Preliminary data suggest that both agents may work synergistically to enhance the efficacy of AML treatment. The study will enroll patients across seven sites in the United States and follow a rigorous treatment regimen.
Read more →ZNTLDocument Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Do
Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Dosed the first patient in a potentially registrational Phase 2 trial
Read more →ZNTLDocument Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demon
Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily
Read more →ZNTLDocument Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 a
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5 Announced strategic collaboration with Te
Read more →ZNTLDocument Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update Announced topline data from the Phase 1 monotherapy dose escalation trial of ZN-c5, its investigational oral SERD, in
Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update Announced topline data from the Phase 1 monotherapy dose escalation trial of ZN-c5, its investigational oral SERD, in patients with ER+ HER2- advanced breast cancer Phase 2 trial expecte
Read more →Competitive Position
How ZNTL ranks across every disease it competes inCompetitive Position is a premium feature
See how ZNTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial